BMYCAUTIOUS

Revenue Growth (YoY)

2.6%

Higher than 36% of Healthcare sector peers

Updated 202h ago

Sector Performance

36th percentile

BMY

2.6%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

The current Revenue Growth (YoY) of 2.6% measures how much BMY’s sales increased over the same quarter last year — a low single-digit gain indicates slow top-line expansion.

This trails the healthcare sector median of 6.2%, placing BMY in the 36th percentile among its peers, meaning the majority of comparable companies grew faster. Because both the year-over-year and quarter-over-quarter changes are marked as N/A, there is no available data to assess a recent trend direction from the last eight quarters. The combination of a below-median growth level with no trend data introduces uncertainty: investors cannot confirm whether this slow growth is a temporary dip or a sustained pattern, which raises ambiguity about future performance. This metric supports the overall CAUTIOUS verdict, as the company’s lackluster revenue increase relative to the sector reinforces a need for careful evaluation rather than clear conviction in the stock’s prospects.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about BMY?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does BMY's Revenue Growth (YoY) compare to its sector?

BMY's Revenue Growth (YoY) of 2.6% compares to a Healthcare sector median of 6.2%, placing it in the 36th percentile.

Who are BMY's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ABT (7.8%), ZBH (9.3%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.